Business Context and Reporting Period
This Form 6-K/A filing by GlaxoSmithKline plc covers the period ending February 2015. The document serves as a notification of transactions involving directors and persons discharging managerial responsibility (PDMRs). Specifically, it details the vesting of dividend shares attached to conditional share awards under the 2009 Performance Share Plan, the 2009 Deferred Annual Bonus Plan, and Matching Share awards granted in 2012.
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data points disclosed are share prices at the time of vesting on February 12, 2015:
- Ordinary Share closing price: £14.855
- American Depositary Share (ADS) closing price: US$45.95
Material Changes and Executive Compensation
The filing reports on the vesting outcomes for the three-year performance period from January 1, 2012, to December 31, 2014. The Remuneration Committee confirmed that 13.5% of the 2012 Performance Share Plan awards vested, with the balance lapsing. Key vesting details include:
- Performance Share Plan: Dividend shares vested for Executive Directors including Sir Andrew Witty (63,989 ADSs), Mr. S. Dingemans (24,636 ADSs), and Dr. M. Slaoui (18,788 ADSs). A portion of Sir Andrew Witty's vested shares (25%) is subject to a two-year holding tranche.
- Deferred Annual Bonus Awards: Dividend shares related to pre-tax awards vested for Executive Directors, with Sir Andrew Witty receiving 8,357 vested shares.
- Matching Shares: Dividend shares related to pre-tax matching awards vested for several executives, while a significant portion lapsed. For example, Sir Andrew Witty had 1,128 vested and 7,229 lapsed ordinary shares.
- PDMRs: Senior executives designated as PDMRs after the initial grant saw their dividend shares lapse entirely (0 vested) for the 2012 Performance Share Plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is strictly a regulatory disclosure regarding equity compensation transactions. The document notes that dividends no longer accrue on the shares following vesting and that nil cost options for Deferred and Matching Shares can be exercised until March 9, 2022.
Investor Verification Checklist
- Verify the 13.5% vesting rate for the 2012 Performance Share Plan against the company's broader performance metrics for the 2012-2014 period.
- Confirm the impact of the "holding tranche" on Sir Andrew Witty's total compensation and share ownership liquidity.
- Review the full list of vested versus lapsed shares to assess executive retention and performance alignment.
- Check subsequent filings for the actual exercise of the nil cost options available until 2022.